Literature DB >> 7000090

Effects of bezafibrate on the serum lipoprotein lipid and apolipoprotein composition, lipoprotein triglyceride removal capacity and the fatty acid composition of the plasma lipid esters.

B Vessby, H Lithell, K Hellsing, A M Ostlund-Lindqvist, I B Gustafsson, J Boberg, H Ledermann.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1980        PMID： 7000090     DOI： 10.1016/0021-9150(80)90011-8

Source DB:  PubMed          Journal:  Atherosclerosis        ISSN： 0021-9150            Impact factor:   5.162


× No keyword cloud information.
  10 in total

1.  Decreased susceptibility to copper-induced oxidation of rat-lipoproteins after fibrate treatment: influence of fatty acid composition.

Authors:  M Vázquez; M Merlos; T Adzet; J C Laguna
Journal:  Br J Pharmacol       Date:  1996-03       Impact factor: 8.739

2.  Apolipoprotein A and B (Sf 100-400) metabolism during bezafibrate therapy in hypertriglyceridemic subjects.

Authors:  J Shepherd; C J Packard; J M Stewart; R F Atmeh; R S Clark; D E Boag; K Carr; A R Lorimer; D Ballantyne; H G Morgan
Journal:  J Clin Invest       Date:  1984-12       Impact factor: 14.808

3.  Bezafibrate fails to directly modulate HMG-CoA reductase or LDL catabolism in human mononuclear cells.

Authors:  E F Stange; M Frühholz; M Osenbrügge; F Reimann; H Ditschuneit
Journal:  Eur J Clin Pharmacol       Date:  1991       Impact factor: 2.953

4.  Stimulation of decreased lipoprotein lipase activity in the tumor-bearing state by the antihyperlipidemic drug bezafibrate.

Authors:  K Nomura; Y Noguchi; A Matsumoto
Journal:  Surg Today       Date:  1996       Impact factor: 2.549

5.  The short term effects of bezafibrate on the hypertriglyceridaemia of moderate to severe uraemia.

Authors:  A J Williams; F Baker; J Walls
Journal:  Br J Clin Pharmacol       Date:  1984-09       Impact factor: 4.335

6.  Increased high density lipoproteins in diabetic children.

Authors:  U Ewald; S Gustafson; T Tuvemo; B Vessby
Journal:  Eur J Pediatr       Date:  1984-08       Impact factor: 3.183

7.  Effects of clofibrate, bezafibrate, fenofibrate and probucol on plasma lipolytic enzymes in normolipaemic subjects.

Authors:  F Heller; C Harvengt
Journal:  Eur J Clin Pharmacol       Date:  1983       Impact factor: 2.953

Review 8.  Bezafibrate. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hyperlipidaemia.

Authors:  J P Monk; P A Todd
Journal:  Drugs       Date:  1987-06       Impact factor: 9.546

9.  Effects of long-term ketoconazole therapy on serum lipid levels.

Authors:  O Rollman; S Jameson; H Lithell
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

10.  Iatrogenic profound hypoalphalipoproteinaemia: an unrecognised cause of very low HDL cholesterol.

Authors:  M J Murphy; A Duncan; B D Vallance; C J Packard; D S O'Reilly
Journal:  Postgrad Med J       Date:  1995-08       Impact factor: 2.401
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.